New $300m fund aimed at helping European biotechs to grow, providing alternative to an IPO or 'generally suboptimal' licensing or big pharma acquisition
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.